Verma Sanjay, Rudraraju Varma S
Centre for Pharmaceutical Sciences, Jawaharlal Nehru Technological University, Kukatpally, Hyderabad, 500 085, India,
AAPS PharmSciTech. 2014 Jun;15(3):641-57. doi: 10.1208/s12249-014-0093-z. Epub 2014 Feb 22.
The objective of the present study was to define a systematic approach to design and prepare solid dispersions of poorly water-soluble drug. The systematic approach can be defined in four phases. In the first phase, glass forming ability is assessed, and in the second phase, probable excipients are screened. The screened excipients are evaluated (third phase) for glass transition temperatures (Tg) and miscibility studies according to Florey-Huggins interaction parameter. The predicted excipients are used to prepare the solid dispersion and evaluated for Tg and any interactions using Fourier transfer infrared studies (fourth phase), and the findings are correlated with phase three predictions. For this investigation, cilostazol (CIL) was selected as model drug, which was classified as a poor glass former. As per the physical chemical properties of CIL, ten excipients, both polymeric and non-polymeric, were selected and screened. Out of these, povidone, copovidone, hypromellose and Eudragit EPO were found theoretically miscible with CIL. After going through phase 2 to phase 4, only povidone, copovidone and hypromellose were confirmed as polymer of choice for preparing the solid dispersion of CIL with a prediction of better physical solid-state stability on the basis of good miscibility between drug and carrier.
本研究的目的是确定一种设计和制备难溶性药物固体分散体的系统方法。该系统方法可分为四个阶段。在第一阶段,评估玻璃形成能力,在第二阶段,筛选可能的辅料。根据弗洛里 - 哈金斯相互作用参数,对筛选出的辅料进行玻璃化转变温度(Tg)评估和混溶性研究(第三阶段)。使用预测的辅料制备固体分散体,并通过傅里叶变换红外光谱研究评估其Tg和任何相互作用(第四阶段),研究结果与第三阶段的预测相关。对于本研究,选择西洛他唑(CIL)作为模型药物,它被归类为不良玻璃形成剂。根据CIL的物理化学性质,选择并筛选了十种辅料,包括聚合物和非聚合物辅料。其中,聚维酮、共聚维酮、羟丙甲纤维素和丙烯酸树脂EPO在理论上与CIL可混溶。经过第二阶段到第四阶段后,仅聚维酮、共聚维酮和羟丙甲纤维素被确认为制备CIL固体分散体的首选聚合物,基于药物与载体之间良好的混溶性,预测其具有更好的物理固态稳定性。